• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.

作者信息

Ambler Graeme K, Nordanstig Joakim, Behrendt Christian-Alexander, Twine Christopher P

机构信息

Bristol Centre for Surgical Research, Bristol Medical School, University of Bristol, UK.

Department of Vascular Surgery and Institute of Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska University Hospital and Academy, Gothenburg University, Sweden.

出版信息

Eur J Vasc Endovasc Surg. 2021 Oct;62(4):654-655. doi: 10.1016/j.ejvs.2021.05.038. Epub 2021 Aug 25.

DOI:10.1016/j.ejvs.2021.05.038
PMID:34452837
Abstract
摘要

相似文献

1
Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.利伐沙班联合阿司匹林与氯吡格雷治疗稳定症状性下肢动脉疾病患者获益的网状Meta分析
Eur J Vasc Endovasc Surg. 2021 Oct;62(4):654-655. doi: 10.1016/j.ejvs.2021.05.038. Epub 2021 Aug 25.
2
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.利伐沙班联合或不联合阿司匹林治疗稳定的外周动脉或颈动脉疾病患者：一项国际、随机、双盲、安慰剂对照试验。
Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10.
3
Rivaroxaban with or without aspirin for prevention of cardiovascular disease.利伐沙班联合或不联合阿司匹林用于预防心血管疾病。
Coron Artery Dis. 2018 Aug;29(5):361-365. doi: 10.1097/MCA.0000000000000605.
4
Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.稳定型冠状动脉疾病和外周动脉疾病的治疗进展
Crit Pathw Cardiol. 2018 Jun;17(2):53-68. doi: 10.1097/HPC.0000000000000149.
5
Rivaroxaban in Peripheral Artery Disease after Revascularization.利伐沙班治疗血管重建术后外周动脉疾病
N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. Epub 2020 Mar 28.
6
Editor's Choice - External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients with Symptomatic Lower Extremity Artery Disease in France: The COPART Registry.编辑精选——法国症状性下肢动脉疾病患者的 COMPASS 和 VOYAGER-PAD 试验的外部适用性：COPART 登记研究。
Eur J Vasc Endovasc Surg. 2021 Sep;62(3):439-449. doi: 10.1016/j.ejvs.2021.05.028. Epub 2021 Jul 28.
7
Short-term effects of rivaroxaban combined with aspirin in the treatment of lower limb arterial atherosclerosis occlusion with stent placement: A retrospective study.利伐沙班联合阿司匹林治疗下肢动脉粥样硬化闭塞症支架置入术后的短期疗效：一项回顾性研究。
Medicine (Baltimore). 2025 Apr 11;104(15):e42147. doi: 10.1097/MD.0000000000042147.
8
VOYAGER PAD contributes to medical therapy for peripheral artery disease.Voyager PAD研究有助于外周动脉疾病的医学治疗。
J Vasc Surg. 2020 Dec;72(6):1843-1844. doi: 10.1016/j.jvs.2020.06.101.
9
A review of antithrombotic therapy and the rationale and design of the randomized edoxaban in patients with peripheral artery disease (ePAD) trial adding edoxaban or clopidogrel to aspirin after femoropopliteal endovascular intervention.抗血栓治疗综述以及外周动脉疾病（ePAD）患者中随机使用依度沙班试验的基本原理和设计：在股腘动脉血管腔内介入术后，将依度沙班或氯吡格雷添加至阿司匹林治疗。
J Endovasc Ther. 2015 Apr;22(2):261-8. doi: 10.1177/1526602815574687.
10
Patient Factors Influencing Prescription of Antithrombotic Medication After Lower Limb Endovascular Intervention.下肢血管内介入治疗后影响抗血栓药物处方的患者因素。
Eur J Vasc Endovasc Surg. 2024 Oct;68(4):510-518. doi: 10.1016/j.ejvs.2024.05.034. Epub 2024 May 25.

引用本文的文献

1
New Horizons in Peripheral Artery Disease.外周动脉疾病的新视野。
Age Ageing. 2024 Jun 1;53(6). doi: 10.1093/ageing/afae114.
2
Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis.抗栓治疗症状性外周动脉疾病：系统评价和网络荟萃分析。
Drugs. 2022 Aug;82(12):1287-1302. doi: 10.1007/s40265-022-01756-6. Epub 2022 Aug 23.